Candel Therapeutics (CADL) Research & Development (2020 - 2025)
Candel Therapeutics (CADL) posted Research & Development of $290000.0 for Q4 2025, down 96.57% sequentially from $8.5 million in Q3 2025, and up 108.41% YoY from $139148.3 in Q4 2024.
Candel Therapeutics (CADL) Research & Development (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Research & Development for 6 years, with the latest figure at $290000.0 in Q4 2025.
- Quarterly Research & Development rose 108.41% year-over-year to $290000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.0 million (up 272.77% YoY) and the FY2025 annual result came in at $937000.0, up 87.78% from the prior year.
- Research & Development slipped to $290000.0 in Q4 2025 per CADL's latest filing, from $8.5 million in the prior quarter.
- Over five years, Research & Development peaked at $8.5 million in Q3 2025 and troughed at -$3.4 million in Q4 2024.
- A 5-year average of $4.1 million and a median of $5.0 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development tumbled 147.51% in 2024, then soared 284.59% in 2025.
- Over 5 years, Research & Development stood at $3.9 million in 2021, then rose by 29.01% to $5.0 million in 2022, then jumped by 45.98% to $7.3 million in 2023, then sank by 147.51% to -$3.4 million in 2024, then soared by 108.41% to $290000.0 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $290000.0, $8.5 million, and $7.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 290,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 290,000.00 |
| Sep 30, 2025 | 8.46 Mn |
| Jun 30, 2025 | 6.99 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 826,000.00 |
| Dec 31, 2023 | 7.26 Mn |
| Sep 30, 2023 | 5.85 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Mar 31, 2023 | 5.47 Mn |
| Dec 31, 2022 | 4.97 Mn |
| Sep 30, 2022 | 5.38 Mn |
| Jun 30, 2022 | 5.02 Mn |
| Mar 31, 2022 | 5.42 Mn |
| Dec 31, 2021 | 3.85 Mn |
| Sep 30, 2021 | 5.27 Mn |
| Jun 30, 2021 | 3.29 Mn |
| Mar 31, 2021 | 2.75 Mn |